ANCA Associated Systemic Vasculitis
6
4
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (6)
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides